Exclusive License and Distribution = Agreement

Regulatory Story

Go=20 to market news section

&= nbsp; =20

Company	Plethora=20 Solutions Holdings PLC	=20
TIDM	PLE
Headline	Exclusive License and Distribution Agreement
Released	07:00 23-Nov-2009
Number	8872C07

RNS Number : 8872C

Plethora Solutions Holdings PLC

23 November 2009

=EF=BB=BF

23rd November 2009

PLETHORA SOLUTIONS AND COLUMBIA LABORATORIES EXECUTE=20 EXCLUSIVE MARKETING AGREEMENT FOR = STRIANT SR=C2=AE

London, UK and=20 Livingston, NJ - November 23, 2009 - Plethora Solutions Holdings PLC = ("Plethora", AIM: PLE) and=20 Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that they have = executed=20 an exclusive license and distribution=20 agreement whereby Plethora will market Columbia's Striant SR=C2=AE 30 mg mucoadhesive buccal tablets for testosterone replacement therapy in men with=20 hypogonadism in the UK. The product received UK marketing approval from the = Medicines and=20 Healthcare Regulatory Authority in=20 2004.

Declining testosterone levels ("late = onset"=20 hypogonadism) are a natural consequence of aging. Epidemiological = studies=20 suggest that over one third of men aged 45 years or more visiting = primary care=20 practices have low testosterone levels and=20 of the eight million men aged between 45 and 65 living in = the UK, it is estimated that over 2.5 million have lower than normal = testosterone levels=20 and might benefit from testosterone replacement therapy. = In some men, low testosterone causes fatigue, lethargy, = loss of=20 libido and erectile dysfunction and in the longer term, a higher risk of = osteoporosis and bone fracture. Low testosterone is more common in men=20 with Type 2 = diabetes and is=20 associated with visceral obesity and insulin resistance. The importance of evaluating = testosterone=20 levels in symptomatic men and the use of testosterone replacement = therapy is=20 recognised by leading authorities including the International Society of = Andrology and the European Association of Urology.

Striant SR=C2=AE is a unique formulation of native testosterone = delivered in a=20 small patch-like tablet which adheres to the buccal mucosa, the small, = natural=20 depression in the mouth where the gum meets the upper lip above the = incisor=20 teeth. As it is exposed to saliva, the product softens into a gel-like = form,=20 which remains comfortably in place over each 12-hour dosing period. = Striant=20 SR=C2=AE releases = testosterone into=20 the blood stream and restores and maintains circulating testosterone at = normal=20 levels. The product will be marketed by = Plethora's=20 newly formed subsidiary, The Urology Company Limited.

Steven Powell, = Chief Executive Officer of Plethora, commented, "The benefits of testosterone replacement therapy are = recognised by=20 urologists and andrologists as an effective means of restoring full = sexual=20 function and increasingly as a means of = better=20 controlling obesity and other symptoms common in men = with diabetes and other metabolic=20 conditions. A = number of=20 testosterone products are available in the UK, such as gels and patches, but we = believe=20 that Striant=E2=84=A2 SR offers=20 patients a convenient alternative."

Columbia Laboratories' Chief Executive = Officer=20 Robert S. Mills stated, "We are=20 pleased that Striant SR=C2=AE will be available to = medical=20 practitioners in=20 the UK and that their male patients = will benefit from its convenience and ability to rapidly = restore normal=20 levels of testosterone."

-Ends-

Enquiries:


Plethora Solutions Steven Powell	Tel : +44(0) 20 3077 = 5400
Hansard Group Adam Reynolds/John = Bick	Tel: +44(0) 20 7245 = 1100

About Plethora:

Plethora is focused on the development = and marketing=20 of products for the treatment of urological disorders. The Company has = products=20 in clinical development for the treatment of overactive = bladder (PSD506), stress urinary=20 incontinence (PSD503),=20 interstitial cystitis (PSD597),=20 gynaecological pain (PSD508),=20 erectile dysfunction (PSD510) and premature = ejaculation=20 (PSD502). The Company is headquartered in=20 the UK and is = listed on=20 the London Stock Exchange (AIM: PLE)

Further information is available = at http://www.plethorasolutions= .co.uk/

About Columbia:

Columbia Laboratories, Inc. is a = specialty=20 pharmaceutical company focused on developing and marketing products for = the=20 reproductive healthcare and endocrinology markets using its novel = bioadhesive=20 drug delivery technology. Further information is available=20 at http://www.columbialabs.com/.

Columbia Laboratories, = Inc.	Investor and Media=20 Contact:
Lawrence A.=20 Gyenes	Melody A. = Carey,
Senior Vice President, Chief = Financial &=20 Treasurer	Co-President, Rx Communications,=20 LLC
(973) 486-8860	(917) = 322-2571

This information is provided by = RNS

The company news service from the = London Stock=20 Exchange

END

AGRCKKKPFBDDADB

London Stock Exchange plc is not = responsible=20 for and does not check content on this Website. Website users are=20 responsible for checking content. Any news item (including any = prospectus)=20 which is addressed solely to the persons and countries specified = therein=20 should not be relied upon other than by such persons and/or = outside the=20 specified countries. Terms=20 and conditions, including restrictions on use and distribution = apply.

=C2=A92009 London=20 Stock Exchange plc. All rights = reserved

Regulatory =